Global health study on hidradenitis suppurativa

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

GHSHS is an international, multicenter observational study led by the University of Zurich to examine healthcare access, treatment patterns, disease severity, and quality of life in people with hidradenitis suppurativa. It uses a combined retrospective and prospective design, gathering standardized data from routine medical records from 2020 onward. The goal is to identify disparities in care and outcomes across healthcare settings. Data are collected from routine clinical care to reflect real-world practice without assigning any experimental interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed General Consent Form, or equivalent document
* Confirmed diagnosis of Hidradenitis Suppurativa

Exclusion Criteria:

* Inability to provide informed consent.
* Datasets with ambiguous or unclear diagnosis.

Where it's running

• University of Zurich
  Zurich, Switzerland Recruiting

Study contacts

• Principal investigator: Julia-Tatjana Maul, Prof. Dr. med. — University of Zurich
• Study coordinator: Julia-Tatjana Maul, Prof. Dr. med.
• Email: julia-tatjana.maul@usz.ch
• Phone: +41 76 441 51 09

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating secukinumab's effectiveness with surgery for hidradenitis suppurativa

  This study is testing if using secukinumab along with surgery can help people with moderate to severe hidradenitis suppurativa feel better and have fewer problems after surgery.

  Recruiting Peking Union Medical College · Nanjing, Jiangsu · NCT06926192

• Soquelitinib in adults with hidradenitis suppurativa

  This study tests whether oral soquelitinib can help adults with moderate-to-severe hidradenitis suppurativa.

  Recruiting at 9 sites Phase 1 Corvus Pharmaceuticals, Inc. · West Lafayette, Indiana and 10 other locations · NCT07828860

• ORKA-002 versus placebo for moderate-to-severe hidradenitis suppurativa

  A study tests ORKA-002 against placebo in adults with moderate-to-severe hidradenitis suppurativa to see if it helps reduce symptoms.

  Recruiting at 25 sites Phase 2 Oruka Therapeutics, Inc. · Birmingham, Alabama and 24 other locations · NCT07783542

• SPY072 in adults with moderate to severe hidradenitis suppurativa

  This study tests whether SPY072 can help adults with moderate to severe hidradenitis suppurativa when added to their current care, compared with a placebo over 16 weeks.

  Recruiting at 7 sites Phase 2 Spyre Therapeutics, Inc. · Birmingham, Alabama and 33 other locations · NCT07766005

• Brain activity patterns in people with hidradenitis suppurativa and how treatments may relate to changes

  This study tests whether adults with hidradenitis suppurativa show different resting brain activity than healthy people and whether these brain patterns relate to symptoms like pain and mood, and whether they change after 3 months of standard biologic or small-molecule treatment.

  Recruiting Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT07755670

• Roflumilast 0.3% Foam for Hidradenitis Suppurativa in Teens and Adults

  This study tests a topical roflumilast foam to see if it improves HS in adolescents and adults over 16 weeks.

  Recruiting Phase 2 Harrison Dermatology · Missouri City, Texas · NCT07689188

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.